PTYLTD
    • Free Reports
  • Pricing
  • About us
  • Contact us
  • Login | Sign up
PTYLTD

Free Reports

Pricing

About us

Contact us

  • Home
  • Insights into ASX Stocks
  • By Topic
  • Insights From Technical Analysis

Insights From Technical Analysis

Zip Co (ASX: ZIP)

Can Zip Co (ASX: ZIP) Maintain Its Breakout Momentum to Clear Near-Term Resistance?

Jun 12, 2026
Proactive Equities Team

Zip Co is recovering from 2026 lows on record earnings, a buyback, and US growth via Stripe. Technically, it broke a downtrend with support near $2.00. Key risks: credit quality, US concentration, and competition.

Genesis Minerals (ASX: GMD)

Can Genesis Minerals (ASX: GMD) Sustain Its Cash Flow Momentum and Break Higher?

Jun 11, 2026
Proactive Equities Team

Genesis Minerals (ASX: GMD) is accelerating production, generating exceptional cash flow, and advancing its Tower Hill growth engine while the stock approaches key breakout levels. We assess fundamentals, catalysts, risks, and technical signals.

VEEM (ASX: VEE)

VEEM (ASX: VEE) Shares Surge Nearly 19% as Factory Expansion Fuels Growth Optimism

Jun 10, 2026
Proactive Equities Team

VEEM shares jumped nearly 19% after completing a major factory expansion. The advanced engineering company is growing its marine, defence, and gyrostabiliser businesses through new products, defence contracts, AUKUS-related opportunities, and increased manufacturing capacity to support future earnings growth.

DXN

From 2 Cents to 14 Cents: DXN Delivers One of the ASX's Biggest Rallies of 2026

Jun 10, 2026
Proactive Equities Team

DXN's share price surged from 2 cents to 14 cents in 2026 after winning major AI and telecommunications infrastructure contracts. The modular data centre specialist is expanding globally, with investors betting on strong growth from AI, cloud, and digital infrastructure markets.

Alterity Therapeutics (ASX: ATH)

Is Alterity Therapeutics (ASX: ATH) Stabilising After Volatility at a Key Technical Level?

Jun 10, 2026
Proactive Equities Team

Alterity Therapeutics (ASX: ATH) is advancing its lead neurodegeneration drug, ATH434, toward Phase 3 trials. Following positive clinical data and a 1-for-50 share consolidation, the stock is holding key technical support around 0.450, awaiting a potential upside breakout.

Hammer Metals (ASX: HMX)

Can Hammer Metals (ASX: HMX) Sustain Its Breakout Above Long-Term Resistance?

Jun 9, 2026
Proactive Equities Team

Hammer Metals, a junior explorer focused on copper, gold and lithium in Queensland and WA, broke above resistance on strong Kalman drilling and a trading halt tied to a potential control deal, though overbought technicals and exploration risk remain.

 

Proactive Equities

At Proactive Equities, we combine deep market expertise with rigorous analysis to deliver stock recommendations you can trust. Our team of seasoned analysts continuously monitor global markets, economic trends, and company fundamentals to identify high-potential investment and trade opportunities.

Company

Home
Pricing
Contact Us
About Us

Resources

ASX Insights
Investing Basics

Links

Privacy Policy
Terms and Conditions
Product Disclosure Statement

Proactive Equities Pty Ltd (ACN: 687 232 471) is a Corporate Authorised Representative (AFSR No. 001318293) of Australia National Investment Group Pty Ltd (ABN: 40 636 343 630), which holds an Australian Financial Services Licence (AFSL no. 522028). The information on this website is general information only and does not constitute personal financial advice. We have not taken the individual circumstances, financial objectives or needs of any investor into account when preparing this information. Investors should consider their circumstances and the relevant PDS for any investment and obtain professional financial and tax advice before making any investment decision. The information on this website is not a recommendation to make any investment or to adopt any particular investment strategy. You should make your own professional assessment of the suitability of this information, relying on your own inquiries. Investments in securities are subject to investment risk. Investment value may go down as wellas up, and investors may not get back the full amount originally invested. Risks include: the investment objective may not be achieved, share market and other market risk, liquidity risk, and currency risk with international investments. Any past performance shown is not an indication of future performance. Commission and other costs charged by executing broker are not considered when calculating past performance. To the extent permitted by law Proactive Equities Pty Ltd accepts no liability for any errors or omissions in, or loss from reliance on the information in this website.

12345...20
Page 1 of 20